Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Aug 26;86(8):593-606.
doi: 10.1016/j.jacc.2025.06.042.

Long-Term Outcomes After Fractional Flow Reserve vs Intravascular Ultrasound to Guide PCI: The FLAVOUR Trial Extended Follow-Up

Collaborators, Affiliations
Randomized Controlled Trial

Long-Term Outcomes After Fractional Flow Reserve vs Intravascular Ultrasound to Guide PCI: The FLAVOUR Trial Extended Follow-Up

Seokhun Yang et al. J Am Coll Cardiol. .

Abstract

Background: The optimal treatment strategy for patients with intermediate coronary stenosis remains uncertain.

Objectives: The aim of this study was to investigate the long-term outcomes of a randomized, open-label, multinational trial comparing fractional flow reserve (FFR)-guided vs intravascular ultrasound (IVUS)-guided treatment strategies.

Methods: Patients aged ≥19 years with de novo intermediate coronary stenosis (40%-70%) and target vessel diameters ≥2.5 mm were randomized 1:1 to FFR- or IVUS-guided treatment across 18 sites in Korea and China. The primary endpoint was a composite of all-cause death, myocardial infarction, and any revascularization occurring after the index procedure. Secondary endpoints included individual components of the primary outcome and per vessel outcomes according to treatment type. Extended follow-up continued through September 2024.

Results: Between July 2016 and August 2019, 1,682 patients were assigned to the FFR-guided (n = 838) and IVUS-guided (n = 844) groups. Over a median follow-up period of 6.3 years (Q1-Q3: 5.6-6.9 years), the primary outcome occurred in 339 patients (22.0%), with no statistically significant difference between groups (179 [23.1%] for FFR vs 160 [20.9%] for IVUS; HR: 1.15; 95% CI: 0.93-1.42; P = 0.208). The revascularization rate after the index procedure was higher in the FFR group (113 [14.9%] vs 87 [11.8%]; HR: 1.32; 95% CI: 1.00-1.75; P = 0.049), particularly for target vessel revascularization (72 [9.6%] vs 44 [6.2%]; HR: 1.67; 95% CI: 1.15-2.43; P = 0.007). Landmark analysis at 2 years and per vessel analyses indicated that the higher revascularization rate after the index procedure was driven primarily by late (2-7 years) revascularizations in vessels in which percutaneous coronary intervention (PCI) was initially deferred. Nevertheless, the overall rate of target vessel PCI, including procedures at index and during follow-up, was significantly lower in the FFR group (38.8% vs 60.5%; P < 0.001), with no statistically significant differences in the annual cumulative incidence of death or myocardial infarction between groups.

Conclusions: FFR-guided and IVUS-guided treatment strategies resulted in comparable long-term outcomes, with no significant difference in patient-oriented composite outcomes. Although FFR-guided treatment was associated with a higher incidence of late target vessel revascularization, the overall target vessel PCI rate, accounting for both the index procedure and revascularization during follow-up, remained significantly lower in the FFR-guided treatment group, with comparable rates of hard outcomes between the 2 groups.

Keywords: coronary artery disease; fractional flow reserve; intravascular ultrasound; long-term outcomes; percutaneous coronary intervention.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures This study was funded by Yuhan Pharmaceutical. The funder had no role in trial design, data collection, analysis, interpretation, or manuscript preparation. Drs Wang and Hu have received an institutional research grant from Boston Scientific. Dr Nam has received an institutional research grant from Abbott. Dr Koo has received institutional research grants from Abbott Vascular, Boston Scientific, Philips, and Yuhan Pharmaceutical. Dr Hahn has received funding from the South Korean National Evidence-Based Healthcare Collaborating Agency, the South Korean Ministry of Health and Welfare, Abbott Vascular, Biosensors, Biotronik, Boston Scientific, Daiichi-Sankyo, Dong-A ST, Hanmi Pharmaceutical, and Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Publication types

LinkOut - more resources